90 CHAPTER 4 54 Krijbolder DI, Verstappen M, van Dijk BT, Dakkak YJ, Burgers LE, Boer AC, Park YJ, de Witt-Luth ME, Visser K, Kok MR, Molenaar ETH, de Jong PHP, Bohringer S, Huizinga TWJ, Allaart CF, Niemantsverdriet E, van der Helm-van Mil AHM. 2022; Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet. 400(10348):283–94. 55 Krijbolder D, Verstappen M, Dijk B van, Dakkak Y, Burgers L, Boer A, Park YJ, Witt M De, Visser K, Kok MR, Molenaar E, Jong P de, Böhringer S, Huizinga T, Allaart C, Niemantsverdriet E, Mil A van der H. 2022; OP0070 Intervention with methotrexate in arthralgia at risk for rheumatoid arthritis to reduce the development of peristent arthritis and its disease burden (TREAT EARLIER): a double-blind, randomised, placebo-controlled trial. Ann Rheum Dis. 81(Suppl 1):48 LP – 49. 56 Schrezenmeier E, Dorner T. 2020; Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 16(3):155–66. 57 Emery P, Durez P, Dougados M, Legerton CW, Becker JC, Vratsanos G, Genant HK, Peterfy C, Mitra P, Overfield S, Qi K, Westhovens R. 2010; Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis. 69(3):510–6. 58 2009. Trial registration: Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients [Internet]. 59 2016. Trial registration: Abatacept Reversing Subclinical Inflammation as Measured by MRI in ACPA Positive Arthralgia (ARIAA) [Internet]. 60 Rech J, Ostergaard M, Tascilar K, Hagen M, Mendez L V, Kleyer A, Kroenke G, Simon D, Schoenau V, Hueber A, Kleinert S, Baraliakos X, Fleck M, Rubbert-Roth A, Behrens F, Kofler D, Feuchtenberger M, Zaenker M, Voll R, et al. 2021; Abatacept Reverses Subclinical Arthritis in Patients with High-risk to Develop Rheumatoid Arthritis -results from the Randomized, Placebo-controlled ARIAA Study in RA-at Risk Patients. Arthritis Rheumatol. 73:939–41. 61 Rech J. 2022; S07.4 Can we inhibit the onset of rheumatoid arthritis? Data from the ARIAA Study. Adv Target Ther. :29–30. 62 Al-Laith M, Jasenecova M, Abraham S, Bosworth A, Bruce IN, Buckley CD, Ciurtin C, D’Agostino M-A, Emery P, Gaston H, Isaacs JD, Filer A, Fisher BA, Huizinga TWJ, Ho P, Jacklin C, Lempp H, McInnes IB, Pratt AG, et al. 2019; Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. Trials. 20(1):429. 63 Pierpont TM, Limper CB, Richards KL. 2018; Past, Present, and Future of Rituximab-The World’s First Oncology Monoclonal Antibody Therapy. Front Oncol. 8:163. 64 Gerlag DM, Safy M, Maijer KI, Tang MW, Tas SW, Starmans-Kool MJF, van Tubergen A, Janssen M, de Hair M, Hansson M, de Vries N, Zwinderman AH, Tak PP. 2019; Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. Ann Rheum Dis. 78(2):179–85. 65 Li G, Zhao J, Li B, Zhang X, Ma J, Ma X, Liu J. 2018; The anti-inflammatory effects of statins on patients with rheumatoid arthritis: A systemic review and meta-analysis of 15 randomized controlled trials. Autoimmun Rev. 17(3):215–25. 66 Yamagata T, Kinoshita K, Nozaki Y, Sugiyama M, Ikoma S, Funauchi M. 2007; Effects of pravastatin in murine collagen-induced arthritis. Rheumatol Int. 27(7):631–9.
RkJQdWJsaXNoZXIy MTk4NDMw